https://www.thehindubusinessline.com/companies/abbott-launches-lab-based-test-to-evaluate-concussions/article69736132.ece Copy Healthcare company Abbott has launched ...

New test will run on Abbott's Alinity® i laboratory instrument, complementing Abbott's rapid i-STAT TBI Plasma test, cleared by the FDA in 2021 Given the significant number of Alinity i instruments in ...

Abbott's Alinity i TBI lab test offers a new reliable result in 18 minutes to help clinicians quickly assess concussion and triage patients. For those with negative results, it rules out the need for ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

Abbott (NYSE: ABT) has announced the global launch of the ACCELERATOR® a3600, a next generation automation solution, to help laboratories address the need to process tests faster while handling ...

Two years after Abbott landed FDA clearance for a hand-held blood test that could detect signs of mild traumatic brain injuries (TBIs) in the span of about 15 minutes, the concussion-spotting test is ...

Abbott Laboratories (NYSE:ABT) posted higher sales of $10.24 billion in the fourth quarter, despite continued soft demand for the company’s Covid-19 testing equipment, beating the consensus of $10.18 ...

The Abbott Laboratories logo is displayed at the company's booth during the Consumer Electronics Show (CES) on January 5, 2022 in Las Vegas, Nevada. (Photo by Patrick T. FALLON / AFP) (Photo by ...

Abbott Laboratories (NYSE:ABT) reports Q3 2023 sales of $10.1 billion, a decrease of 2.6% due to anticipated decline in COVID-19 testing-related sales. Company's GAAP diluted EPS stands at $0.82, with ...